[A22-74] Inebilizumab (neuromyelitis optica spectrum disorders [NMOSD]) – Benefit assessment according to § 35a SGB V
Last updated 02.11.2022
Commission awarded on 19.07.2022 by the Federal Joint Committee (G-BA).
Head and nerves
Adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin-4 immunoglobulin G seropositive
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.